에 대한 최신 뉴스 Elanco Animal Health (NYSE:ELAN) 주식

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Analyst Color

Biotech

Large Cap

News

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are bouncing around Monday morning. The company announced it surpassed its year-end operating hashrate guidance and <a href="https://www.benzinga.com/pressreleases/24/12/n42644639/cleanspark-exceeds-2024-year-end-guidance-of-37-ehs-and-accelerates-2025-guidance">accelerated its outlook for 2025</a>. 
What Happened: CleanSpark said it has achieved and exceeded the previously announced year-end target of 37 EH/s and now has 37.5 EH/s of operating hashrate after its newest data centers in Tennessee and Wyoming were energized last week. The company expects to exceed 50 EH/s in the first half of 2025.
CleanSpark noted that fleet efficiency has reached 17.7 J/Th and is expected to improve as the company continues its strategic growth plans. 
CleanSpark expects to achieve its growth targets through a mix of greenfield infrastructure development, organic growth via existing site expansion and strategic M&amp;A. All growth is expected to be funded with a portion of the proceeds of the company&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42558246/cleanspark-is-outpacing-bitcoin-mining-peers-wednesday-whats-going-on">most recent offering</a>.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42644568/institutional-crypto-adoption-for-real-this-time-says-messari">Institutional Crypto Adoption &#8216;For Real This Time,&#8217; Says Messari</a>
&#8220;Our teams have been hard at work throughout the entirety of this past year. We have delivered on our ambitious targets and expanded our hashrate nearly&nbsp;300%&nbsp;since the beginning of 2024. Achieving 37.5 EH/s with a fleet efficiency of 17.7 J/Th is a significant milestone, and we intend to continue adding highly efficient hashrate through the end of the year and into 2025,&#8221; said Zach Bradford, CEO and president of CleanSpark.
&#8220;Our growth and efficiency have resulted in a&nbsp;bitcoin&nbsp;treasury balance quickly approaching 10,000&nbsp;bitcoin, all of which we have mined. As we look to 2025, we intend to remain focused on&nbsp;bitcoin&nbsp;and mining efficiently utilizing operational excellence at scale.&#8221;
CleanSpark shares initially traded higher when the company announced the operating update. The stock began moving lower as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) traded lower early Monday. Bitcoin was down about 2.12% over a 24-hour period, trading around $94,950 at the time of publication.
CLSK Price Action: <a href="http://benzinga.com/quote/clsk">CleanSpark shares</a> were down 1.26% at $11.00 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

Movers

$BTC

CLSK

What's Going On With CleanSpark Stock Monday?

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.08%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Overweight rating and raised the price target from $40 to $43 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $33 to $39 on Sept. 4. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Oct. 30, Omega Healthcare Investors reported better-than-expected third-quarter financial results and raised its FY24 adjusted FFO guidance.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OHI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png" alt="" class="wp-image-704244" style="width:688px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085216/image-188-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.60%</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and raised the price target from $17 to $18 on Dec. 18. This analyst has an accuracy rate of 76%.</li>
<li>Barrington Research analyst James Goss maintained an Outperform rating with a price target of $21 on Nov. 13. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 12, Outfront Media posted mixed quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1">latest OUT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png" alt="" class="wp-image-704245" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085251/image-189-768x717.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
<h3 class="wp-block-heading">LTC Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>)</h3>
<ul>
<li>Dividend Yield: 6.50%</li>
<li>Wells Fargo analyst Connor Siversky assumed an Equal-Weight rating and raised the price target from $36 to $37 on Oct. 1. This analyst has an accuracy rate of 65%.</li>
<li>Wedbush analyst Richard Anderson reiterated an Outperform rating and a price target of $40 on Sept. 20. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: LTC named Wendy Simpson Executive Chairman Of The Board, promoted Pam Kessler and Clint Malin to co-Chief Executive Officers, and Cece Chikhale Tto Chief Financial Officer, effective Dec. 31.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"> trend in LTC stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png" alt="" class="wp-image-704248" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23085334/image-190-768x716.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Dividends

Price Target

Pre-Market Outlook

Markets

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks Delivering High-Dividend Yields

XBIT

Trading Halt: Halted at 8:55:10 a.m. ET - Trading Halt: Halt News Pending

Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares are trading higher premarket on Monday. On Sunday, the company disclosed securing around <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42639115/faraday-future-secures-30-million-financing-to-strengthen-the-companys-core-business-and-continued" rel="noreferrer noopener">$30 million in cash financing commitments</a>.
The financing comprises $7.5 million pre-funded in the fourth quarter of 2024 and $22.5 million in new cash commitments structured as unsecured convertible notes and warrants.
The Convertible Notes have a conversion price of $1.16 per share, while the Warrants are exercisable at $1.392 per share, subject to adjustments.
The underlying shares are currently unregistered and not immediately tradable. The financing remains subject to customary closing conditions.
The funds will support the development of Faraday X (FX). The company is targeting the mainstream U.S. EV market with plans to deliver its first two FX prototype mules to Los Angeles later this month.
Product development and testing will commence at the company's Hanford, CA, manufacturing facility.
FFIE CEO Matthias Aydt said, "The new funding lays a solid foundation for both FF and its new brand as the Company approaches the end of 2024 and enters the new year."
"I am optimistic about the opportunities that this new funding will bring, including supporting the ongoing production of our FF 91 2.0 and the growth of the FX brand."
Last month, the company announced the launch of a development phase after its first FX <a target="_blank" href="https://www.benzinga.com/news/global/24/11/42092678/whats-going-on-with-faraday-future-intelligent-electric-stock" rel="noreferrer noopener">prototypes&nbsp;arrived at its headquarters</a>.
Price Action: FFIE shares are up 12.07% at $1.3000 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41541997/revving-up-in-the-middle-east-faradays-new-uae-headquarters-solidifies-ev-expansion-strategy" target="_blank" rel="noreferrer noopener">Revving Up In The Middle East: Faraday's New UAE Headquarters Solidifies EV Expansion Strategy</a></li>
</ul>
Photo Courtesy of Faraday Future Intelligent Electric

Equities

Financing

Small Cap

FFIE

Why Is Faraday Future Intelligent Electric Trading Higher On Monday?

IKNA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

WIIM

AILE

iLearningEngines shares are trading lower after the company announced it voluntarily filed for Chapter 11 Bankruptcy,

RBC Capital analyst Gregory Renza reiterates Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Outperform and maintains $68 price target.

Reiteration

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

RBC Capital Reiterates Outperform on Jasper Therapeutics, Maintains $68 Price Target

Truist Securities analyst Michael Lewis maintains National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) with a Hold and lowers the price target from $78 to $72.

Truist Securities Maintains Hold on National Health Investors, Lowers Price Target to $72

RAPT

RAPT Therapeutics shares are trading higher after the company announced a partnership with Shanghai Jemincare Pharmaceutical for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody.

Macro Economic Events

Econ #s

Economics

USA Core Durable Goods Orders (MoM) For November -0.1% Vs 0.2% Prior

RBC Capital analyst Steven Shemesh reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Outperform and maintains $130 price target.

OLLI

RBC Capital Reiterates Outperform on Ollie's Bargain Outlet, Maintains $130 Price Target

USA Durables Excluding Defense (MoM) For November -0.3% Vs 0.5% Prior

U.S. stocks settled higher on Friday, with the Dow Jones index surging almost 500 points during the session.
Even as the major indices recorded gains on Friday, all three averages fell last week. The Dow dipped around 2.3% to record its third losing week in a row. The S&amp;P 500 declined about 2%, while the Nasdaq Composite fell around 1.8% last week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Reiterated a Neutral rating on Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) with a price target of $164 on Dec. 19. This analyst sees around 19% upside in the stock.</li>
<li>Recent News: On Dec. 18, Lennar reported worse-than-expected fourth-quarter financial results.</li>
</ul>
Analyst: Andres Sheppard
<ul>
<li>Analyst Firm: Cantor Fitzgerald</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained an Overweight rating on Archer Aviation Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and raised the price target from $10 to $13 on Dec. 18. This analyst sees around 34% upside in the stock.</li>
<li>Recent News: On Dec. 12, Archer announced a partnership with Anduril to develop hybrid VTOL military aircraft and reported raising an additional $430 million in equity capital.</li>
</ul>
Analyst: Doug Anmuth 
<ul>
<li>Analyst Firm: JP Morgan</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Overweight rating on Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and raised the price target from $250 to $280 on Dec. 18. This analyst sees around 24% upside in the stock.</li>
<li>Recent News: Amid peak holiday shopping, Amazon.com recently announced that its operations will remain unaffected despite a strike initiated by workers at seven of its U.S. facilities.</li>
</ul>
Analyst: Jessica Reif Ehrlich
<ul>
<li>Analyst Firm: B of A Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Fox Corporation &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) and increased the price target from $50 to $55 on Dec. 18. This analyst sees around 11% surge in the stock.</li>
<li>Recent News: On Dec. 17, Fox announced its digital presence reached 2.4 billion total multiplatform views in November.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and decreased the price target from $175 to $140 on Dec. 19. This analyst sees around 55% upside in the stock.</li>
<li>Recent News: On Dec. 18, Micron reported first-quarter revenue of $8.71 billion, missing the consensus estimate of $8.72 billion.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Long Ideas

ACHR

AMZN

FOXA

This Analyst With 86% Accuracy Rate Sees Around 24% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

Macro Notification

USA Durable Goods Orders (MoM) For November -1.1% Vs 0.3% Prior

Truist Securities analyst Jamie Cook reiterates AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and lowers the price target from $116 to $109.

AGCO

Truist Securities Reiterates Buy on AGCO, Lowers Price Target to $109

GTBP

GT Biopharma shares are trading higher. Roth MKM initiated coverage on the stock with a Buy rating and set its price target at $11.

Agnico Eagle Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AEM#TSX">AEM</a>)&nbsp;("Agnico Eagle") announced today that it has completed a transaction with ONGold Resources Ltd. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ONAU#TSXV">ONAU</a>) ("ONGold") which resulted in Agnico Eagle acquiring 8,700,000 common shares ("Common Shares") of ONGold.
On November 25, 2024, Yamana Gold Ontario Inc. ("Yamana"), a wholly-owned subsidiary of Agnico Eagle, and 10215825 Manitoba Ltd. (the "Buyer"), a wholly-owned subsidiary of ONGold, entered into an asset purchase agreement, pursuant to which the Buyer agreed to purchase certain assets from Yamana in exchange for, among other things, the issuance of Common Shares to Agnico Eagle (the "Transaction"). On December 20, 2024, the Transaction was completed, which resulted in Agnico Eagle acquiring 8,700,000 Common Shares.
Agnico Eagle currently owns 8,700,000 Common Shares, representing approximately 15.0% of the issued and outstanding Common Shares on a non-diluted basis. Prior to the closing of the Transaction, Agnico Eagle did not own any Common Shares.
In connection with closing of the Transaction, Agnico Eagle and ONGold entered into an investor rights agreement pursuant to which ONGold granted Agnico Eagle certain rights, provided that Agnico Eagle maintains certain ownership thresholds in ONGold, including: (a) the right to participate in equity financings and top-up its holdings in relation to dilutive issuances in order to maintain its pro rata ownership interest in ONGold at the time of such financing or acquire up to a 19.99% ownership interest in ONGold; and (b) the right (which Agnico Eagle has no present intention of exercising) to nominate one person (and in the case of an increase in the size of the board of directors of ONGold to eight or more directors, two persons) to the board of directors of ONGold.

TSX:AEM

TSXV:ONAU

Agnico Eagle Acquires 8.7M Shares Of ONGold, Secures 15% Stake; Granted Rights To Boost Holdings Up To 19.99%

<a href="https://www.globenewswire.com/Tracker?data=3IO2gUzW7Cw-Q-FQqDZQbgLiiQ15aDUo_4CXaPHofKgijz46bDoLlvDH-Fk4Z6ygMULR9uH-DRpTw3HQ5bSqk1TB6EK6oPj8GjxiZBN4BQc=">OptimizeRx Corp.</a> (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition.

Management

OPRX

OptimizeRx CEO William Febbo To Depart, Announces Appointment Of Stephen Silvestro As Interim CEO, Effective As Of December 31, 2024

Prestige Wealth shares are trading higher after the company announced it regained Nasdaq Compliance.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;That business is <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">smoking hot,&#8221; he added</a>.
On Dec. 17, Morgan Stanley analyst Meta Marshall maintained Arista Networks with an Overweight and raised the price target from $102.5 to $118.
Cramer said Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) is a &#8220;great spec.&#8221; However, he recommended being careful.
On Dec. 12, Under Armor reiterated its FY25 guidance.
When asked about Texas Pacific Land Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>), he said, &#8220;We have liked it, but it's now gone up so much. I've got to tell you, I want to hold off.&#8221;
On Nov. 6, Texas Pacific Land posted weaker-than-expected quarterly sales.
Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) is a &#8220;terrific&#8221; stock, Cramer said. "I like the LNG market now that we have President-elect Trump coming in because he's pro LNG.&#8221;
On Oct. 31, Cheniere Energy reported better-than-expected third-quarter financial results and raised its FY24 adjusted EBITDA guidance. Cheniere Energy reported quarterly earnings of $3.93 per share which beat the analyst consensus estimate of $1.87 per share. The company reported quarterly sales of $3.763 billion which beat the analyst consensus estimate of $3.729 billion.
Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is a buy, the &#8220;Mad Money&#8221; host said.
Wells Fargo Bank lowered its prime rate to 7.50% from 7.75%, effective Dec. 19, 2024.
&#8220;These are really good companies, you have to buy them when they're low,&#8221; Cramer said when asked about CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>).
CSX will release fourth quarter financial and operating results after the closing bell on Thursday, Jan. 23, 2025.
&#8220;You want to hold on to Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). You know, Eaton is a buy and hold story,&#8221; Cramer said. &#8220;Do not sell, own.&#8221;
On Dec. 9, Citigroup analyst Andrew Kaplowitz maintained Eaton with a Buy and raised the price target from $394 to $440.
Price Action:
<ul>
<li>Cheniere Energy shares gained 1.4% to settle at $208.89 on Friday.</li>
<li>Arista shares rose 3.4% to close at $112.81 during the session.</li>
<li>Eaton shares rose 0.7% to settle at $338.12.</li>
<li>Texas Pacific Land shares gained 3.4% to settle at $1,133.12 on Friday.</li>
<li>Under Armour shares gained 2.9% to $7.78 on Friday.</li>
<li>Wells Fargo shares gained 2.2% to settle at $70.34 on Friday.</li>
<li>CSX shares gained 0.9% to close at $31.85.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/author/avi-kapoor">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Media

ANET

Jim Cramer Says Under Armour Is A 'Great Spec,' Recommends Buying This Big Bank Stock

Elanco Animal Health ( ($ELAN) ) has provided an update. Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, enhancing its ...

Elanco Animal Health Strengthens Board with New Appointment

In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Elanco Animal Health (ELAN – Research Report), with a price t...

Jefferies Keeps Their Buy Rating on Elanco Animal Health (ELAN)

Elanco (ELAN) Animal Health acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Spe...

Elanco acquires contract manufacturing facility in Speke, UK

Elanco buys key U.K. manufacturing site for $25M

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Oppenheimer's top Buy and Sell ideas from each of the sectors

A class action lawsuit was filed against Elanco Animal Health Inc. ($ELAN) by Levi & Korsinsky on October 7, 2024. The plaintiffs (shareholders) al...

Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)

Zoetis: Healing Paws, Growing Profits

Leerink analyst Daniel Clark initiated coverage of Elanco (ELAN) with a Market Perform rating and $14 price target The firm notes Elanco trades at ...

Elanco initiated with a Market Perform at Leerink

UBS initiated coverage of Elanco (ELAN) with a Buy rating and $18 price target The shares are down 19% year-to-date and 7% last week alone on Zenre...

Elanco initiated with a Buy at UBS

ANDE

BIIB

BNTX

CARS

CWEN

CYBR

HWKN

LMAT

LSCC

MRNA

MSGS

NAVI

PGNY

VRTX

Press Releases

ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit

Class Action Filed Against Elanco Animal Health Incorporated (ELAN) - December 6, 2024 Deadline to Join - Contact Levi & Korsinsky

Legal

ELAN CLASS ACTION DEADLINE IS TODAY: Elanco Investors are Alerted of December 6 Deadline in Securities Fraud Class Action – Contact BFA Law Now (NYSE:ELAN)

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health

ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco Animal Health Incorporated shares should contact the Shareholders Foundation

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines – ELAN

Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Leerink Partners

Barclays

Stifel

Morgan Stanley

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Elanco Animal Health

뉴스

에 대한 최신 뉴스 Elanco Animal Health (NYSE:ELAN) 주식

월요일, 12월 23, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌